The Kirby Institute for infection and immunity in society, University of New South Wales, Sydney, NSW, Australia.
Med J Aust. 2012 Jun 4;196(10):629-32. doi: 10.5694/mja11.11531.
The next decade will be a crucial period in the public health response to hepatitis C virus (HCV) infection. The rapid development of direct-acting antiviral therapy for HCV infection has brought considerable optimism to the HCV sector, with the realistic hope that therapeutic intervention will soon be more effective and offer shorter treatment duration. The initial phase of combination pegylated interferon, ribavirin and a protease inhibitor will be associated with increased toxicity and complexity of therapeutic management but, over the course of the decade, strategies including interferon-free combination direct-acting antiviral regimens with enhanced tolerability and simplified dosing schedules and monitoring protocols will emerge.
下一个十年将是应对丙型肝炎病毒（HCV）感染的公共卫生反应的关键时期。直接作用抗病毒疗法在 HCV 感染方面的快速发展为 HCV 领域带来了相当大的乐观情绪，人们真切地希望治疗干预将很快更有效，并提供更短的治疗持续时间。最初的聚乙二醇干扰素、利巴韦林和蛋白酶抑制剂联合治疗阶段将与更高的毒性和更复杂的治疗管理相关联，但在这十年中，将出现包括无干扰素联合直接作用抗病毒方案在内的各种策略，这些方案具有更好的耐受性和简化的剂量方案和监测方案。
